Immunosuppressive Pathways in Cutaneous Melanoma: Functional Integration Between PD-1 and CD73 and Therapeutic Implications
Open Access
- 9 June 2026
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 913
Abstract
Background: Cutaneous melanoma (CM) is a highly immunogenic malignant neoplasm. It features high mutational burden and intense lymphocytic infiltration, supporting the use of immunotherapies, especially inhibitors of the programmed cell death protein 1 (PD-1) checkpoint. Despite advances with anti-PD-1 therapies, such as nivolumab and pembrolizumab, many patients still experience resistance. This result highlights additional immunosuppressive mechanisms within the tumor microenvironment (TME) that limit T-lymphocyte-mediated responses. Objectives: The aim was to discuss the immunologic and metabolic bases of PD-1- and CD73-mediated pathways and evidence that CD73 inhibition can boost PD-1 inhibitor efficacy by acting on convergent immunosuppressive pathways. Methods: We conducted a narrative literature review focusing on tumor immunosuppression, purinergic signaling and checkpoint inhibitor-based immunotherapy. Results: The purinergic pathway, mediated by the ectonucleotidase CD73, is a critical regulator of tumor immunosuppression. CD73 converts extracellular adenosine monophosphate (AMP) into adenosine. This adenosine accumulates in the hypoxic and inflamed TME, exerting immunosuppressive effects. Adenosine acts as a “metabolic brake,” inhibiting proliferation, cytokine production, and cytotoxic activity of CD8+ T lymphocytes and natural killer (NK) cells. It also promotes the expansion of regulatory T cells (Tregs) and tumor progression. This axis may limit responses to PD-1 blockade, suggesting that complementary pathways are active. Conclusions: Integration of PD-1 and CD73 pathways suggests that CD73 inhibition may enhance PD-1 blockade by targeting convergent immunosuppressive mechanisms. This supports the exploration of combination strategies to broaden the benefits of immunotherapy in CM.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (Instituto Nacional Sinalização Purinérgica: Desafios para a saúde do século 21)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (409156/2024-8)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (305974/2025-4)
- Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina (2023TR001472)
- Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina (2024TR002502)
- Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina (2025TR001686)
- Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina (2026TR000240)
This publication has 139 references indexed in Scilit:
- Inhibition of Melanoma Growth by Ex Vivo Expanded Tumor‐Specific CD8+ T Cells Is Dependent on the Configuration of Nanoscale Artificial APCsEuropean Journal of Immunology, 2025
- Co‐Delivery of aPD‐L1 and CD73 Inhibitor Using Calcium Phosphate Nanoparticles for Enhanced Melanoma Immunotherapy with Reduced ToxicityAdvanced Science, 2024
- The clinicopathological impact of tumor‐associated macrophages in patients with cutaneous malignant melanomaJournal of Surgical Oncology, 2023
- First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumorsCancer Immunology, Immunotherapy, 2023
- Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040JAMA Dermatology, 2022
- Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer modelsCancer Immunology, Immunotherapy, 2018
- Melanoma: What do all the mutations mean?Cancer, 2018
- Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protectionJournal of Molecular Medicine, 2014
- Extracellular adenosine metabolism in immune cells in melanomaCancer Immunology, Immunotherapy, 2014
- Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cellsCancer Immunology, Immunotherapy, 2008